ALLMedicine™ Central Retinal Vein Occlusion Center

Mar 18th, 2023 - Satoyoshi syndrome is a rare systemic autoimmune disease that presents with painful muscle spasms. We report a case of impending central retinal vein occlusion (CRVO) secondary to granulomatous pan-uveitis in a 32-year-old woman with Satoyoshi syn...

Mar 14th, 2023 - Neovascular glaucoma (NVG) is a sight-threatening condition that is often refractory to treatment. Current management principles are yet to be standardized due to lack of evidence. We studied the interventions used to treat NVG at Sydney Eye Hospi...

Feb 28th, 2023 - This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals unt...

Feb 24th, 2023 - The global protein profile of the aqueous humor has been found to correlate with the severity of retinal vascular disease. Studying the aqueous humor in central retinal vein occlusion (CRVO) with proteomic techniques may bring insights to the mole...

Feb 23rd, 2023 - Waldenström macroglobulinemia is a rare hematological malignancy and is the most common diagnosis in patients with hyperviscosity syndrome. Bilateral central retinal vein occlusion as an initial presentation of hyperviscosity syndrome in Waldenstr...

Feb 28th, 2023 - This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals unt...

Feb 17th, 2023 - The primary objective is to assess the safety of intravitreal aflibercept injections in patients with wet age-related macular degeneration (wAMD), myopic choroidal neovascularization (mCNV), diabetic macular edema (DME), macular edema secondary to...

Feb 15th, 2023 - The goal of this phase I/II prospective, randomized, sham-controlled, double-masked clinical trial is to determine whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from c...

Jan 30th, 2023 - The study included Screening Period (Day -28 to Day -1), double-masked treatment period (Day 1 to Week 72), and post-treatment follow-up period (Week 72 to Week 76). Treatment visits were scheduled in 4-week intervals. After 6 initial monthly inje...

Jan 30th, 2023 - Periodontitis is a chronic low-grade bacterial infection of supporting tissue of teeth. Chronic periodontitis is often non symptomatic. Inflammation is located usually in deepened periodontal pockets (> 4mm or >6mm) and it leads to alveolar bone l...

Oct 28th, 2022 - Note that some links may require subscriptions. Outpatient COVID treatment with nirmatrelvir-ritonavir (Paxlovid) was 36% and 30% lower for Black and Hispanic patients compared with white patients, a CDC report found. A high proportion of recovere...

May 14th, 2019 - The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron) injection solution to treat all stages of diabetic retinopathy, the manufacturer has announced. Aflibercept, a vascular endothelial growth factor (VEGF) inhibito...

May 14th, 2019 - The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron Pharmaceuticals) injection solution to treat all stages of diabetic retinopathy, the manufacturer has announced. Aflibercept, a vascular endothelial growth factor...

Nov 19th, 2017 - Development of technologies for sustained drug delivery is a topic of great interest among retina specialists, considering the number of chronic conditions that are managed with repeated intravitreal injections. Products in this category are alrea...

Jul 24th, 2017 - Case Diagnosis Isolated chronic elevation of the optic disc with relatively preserved visual function raises suspicion for vitreopapillary traction (VPT). This diagnosis can be confirmed by OCT, as it was in this patient. Idiopathic intracranial h...